Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India. 2012

S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.

Objective. The increased use of antiretroviral therapy (ART) has reduced the morbidity and mortality associated with HIV, adversely leading to the emergence of HIV drug resistance (HIVDR). In this study we aim to evaluate the prevalence of HIVDR mutations in ART-naive HIV-1 infected patients from northern India. Design. Analysis was performed using Viroseq genotyping system based on sequencing of entire protease and two-thirds of the Reverse Transcriptase (RT) region of pol gene. Results. Seventy three chronic HIV-1 infected ART naïve patients eligible for first line ART were enrolled from April 2006 to August 2008. In 68 patients DNA was successfully amplified and sequencing was done. 97% of HIV-1 strains belonged to subtype C, and one each to subtype A1 and subtype B. The overall prevalence of primary DRMs was 2.9% [2/68, 95% confidence interval (CI), 0.3%-10.2%]. One patient had a major RT mutation M184V, known to confer resistance to lamivudine, and another had a major protease inhibitor (PI) mutation D30N that imparts resistance to nelfinavir. Conclusion. Our study shows that primary HIVDR mutations have a prevalence of 2.9% among ART-naive chronic HIV-1 infected individuals.

UI MeSH Term Description Entries

Related Publications

S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
August 2012, AIDS research and human retroviruses,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
December 2011, AIDS research and human retroviruses,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
January 2007, HIV clinical trials,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
January 2015, AIDS research and therapy,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
January 2010, Advances in virology,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
April 2024, Global health & medicine,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
July 2011, AIDS research and human retroviruses,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
July 2022, Medicine,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
March 2012, Journal of the International AIDS Society,
S Sinha, and H Ahmad, and R C Shekhar, and N Kumar, and L Dar, and J C Samantaray, and S K Sharma, and A Bhargava, and R M Pandey, and R L Mitsuyasu, and J L Fahey
November 2005, HIV medicine,
Copied contents to your clipboard!